Raymond James & Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Raymond James & Associates’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,701	Closed	-$439K	–	4129
2021 Q1	$439K	Buy	5,701 +798	+16%	+$73.5K	﹤0.01%	3118
2020 Q4	$485K	Buy	4,903 +1,111	+29%	+$136K	﹤0.01%	2829
2020 Q3	$538K	Buy	3,792 +418	+12%	+$69.7K	﹤0.01%	2561
2020 Q2	$666K	Buy	3,374 +958	+40%	+$198K	﹤0.01%	2415
2020 Q1	$473K	Buy	2,416 +201	+9%	+$43.2K	﹤0.01%	2458
2019 Q4	$458K	Buy	2,215 +581	+36%	+$107K	﹤0.01%	2794
2019 Q3	$249K	Buy	+1,634	New	+$268K	﹤0.01%	3120

Other funds holding LKFT

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James & Associates's LKFT Position: Q2 2021 in Review

Raymond James & Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2021, closing a stake of 5,701 shares — an estimated $439K sold.

Raymond James & Associates first reported a position in LKFT in Q3 2019 and held it in 7 quarters. The position peaked at $666K in Q2 2020. 108 funds tracked by Wall St. Rank hold LKFT as of Q2 2021.

Raymond James & Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2021 after selling out during the quarter.
Raymond James & Associates sold 5,701 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2021, an estimated $439K.
Raymond James & Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2019 and held it in 7 quarters.
Raymond James & Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $666K in Q2 2020.
108 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.